Deutsche Märkte geschlossen

Amgen Inc. (AMGN)

NasdaqGS - NasdaqGS Echtzeitpreis. Währung in USD
Zur Watchlist hinzufügen
219,38+2,02 (+0,93%)
Börsenschluss: 4:00PM EDT
219,54 0,16 (0,07%)
Nachbörse: 05:30PM EDT
Melden Sie sich an, um eine Nachricht zu posten.
  • a
    ageninrussia
    KRAS is stealing the show

    $AMGN combination treatment with KRAS-blocking drug shows improved response in colon cancer patients $MRTX
  • j
    j
    $ARWR conversation
    Credit Truth on twitter:
    Notable that $AMGN is demonstrating a new level of confidence in $ARWR TRiM
    Trade mark sign
    by their manner of promoting progress with Lipoprotein(a) w/ AMG-890 formerly Arrowhead’s ARO-LPA https://amgenscience.com/features/10-things-to-know-about-lipoproteina/
    Seems this blockbuster drug is moving quickly enough to merit this Amgen PR.
    https://www.amgenscience.com/features/10-things-to-know-about-lipoproteina/
    10 Things to Know About Lipoprotein(a) - Amgen Science
    www.amgenscience.com
  • T
    Tad
    $ARWR conversation
    bbs moonlighting on twitter: Lp(a) Major Risk Factor for Heart Disease. Big news out of deCODE regarding Lp(a). Directly relevant to $ARWR's AMG 890, that targets Lp(a), licensed to $AMGN. Must be leading up to something big coming out soon.
    https://www.prnewswire.com/news-releases/beyond-cholesterol-landmark-decode-study-elucidates-role-of-lipoproteina-as-major-risk-factor-for-heart-disease-300971592.html
    /PRNewswire/ -- Scientists at deCODE genetics and colleagues from the National University Hospital in Iceland today present the largest-scale study to date of...
    /PRNewswire/ -- Scientists at deCODE genetics and colleagues from the National University Hospital in Iceland today present the largest-scale study to date of...
    www.prnewswire.com
  • T
    Tad
    $ARWR conversation
    amgn just won approval for kras blocking lung cancer drug....
    from twitter: "You have to give $AMGN credit here...moved at lightning speed, AMG 510 only began enrolling for P1 in July of 2018"
    lets put hif2 on a similar timeline/path
  • C
    Chris
    $ARWR conversation
    Taken from Mark C on Twitter:So lets recap, $ARWR & its partners $AMGN / $JNJ will be presenting data on 5 of ARWR #RNAi drugs in the coming days at #AASLDglobal & #AHA2020 . This is unprecedented, especially when you consider the marketsize/blockbuster status of at least 4 of these drugs. FIVE! #HBV #AAT
  • K
    Kim
    $SRPT conversation
    FromSY investing:
    Cantor 2020 #biotech outlook

    Top picks:
    - Large-cap: $VRTX $AMGN
    - Mid-cap: $SRPT $ALNY
    - Small-cap: $TGTX $ICPT $GBT $AGIO
    - Favorite binary: $MYOK
  • M
    Michael007here
    AMG 890

    A Phase 2 study in patients with cardiovascular disease has commenced for AMG 890, a small interfering RNA molecule that lowers lipoprotein(a). $ARWR $AMGN
  • A
    AIKIDO
    $AMRN , JT presentation today is super strong BP wake up and buyout this company even at $50B looks cheap going forward $PFE $AMGN. $NVS. $GSK spend the money it’s worth it, ADA Standard of Care , Diabetes community is a very lucrative big market 90 million of them according to JT , wow that alone counts in BILLIONS, JT always says we’re not competing in Statins $500B markets but Triglycerides and Cholesterol is entangled now that will take many BILLIONS from that, Atherosclerosis, Alzheimer’s and Cancers future collaborators are looking at that too, AMRN is severely undervalued here and should be close to $100/Shares, A game changer just like $BYND and $UBER in each industry
  • C
    Chris
    $ARWR conversation
    The Ravid on Twitter this morning :$ARWR has vast pipeline including several later stage assets, partnership with Janssen $JNJ for multiple assets, license with Amgen $AMGN; if they do 1 drug w/$1B sales @ 4x multiple (on a sale), you cover the current valuation, get the rest of platform and pipeline free.
  • V
    VegasMD
    Bio boom on Twitter —is this correct?

    $SRNE Partnership with $AMGN in a phase 1b study using Sorrento Therapeutics SOFUSA technology. New clinical trial!
  • T
    Tad
    $ARWR conversation
    interesting take on twiter from dave c: Interesting Mamtani was at Leerink analyst from 2014 -16, then $AMGN for 2 1/2 years mainly in corporate development (Looking at Partnership deals and M&A) Now at B Riley since 2018 he views $ARWR as "Amgen in the making" He certainly has the experience to back that perspective.
  • T
    Tad
    $ARWR conversation
    from bbs on twitter: Yet another $AMGN patent application referencing #RNAi as the preferred modality to treat acute myeloid leukemia (AML). Most likely partner = $ARWR. No publicly announced partnership yet.https://patents.google.com/patent/US20170037133A1
    The present invention provides an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT for use in a method of treatment of a blood-borne cancer, in particular acute myeloid leukemia (AML). Moreover, the present inven
    The present invention provides an inhibitor against CD112 (Nectin-2, PVRL2), CD155 (PVR), Galectin-9, TIM-3 and/or TIGIT for use in a method of treatment of a blood-borne cancer, in particular acute myeloid leukemia (AML). Moreover, the present inven
    patents.google.com
  • R
    Russ
    OMER is the 2019 recipient of the Nobel Prize Of Pharma, The Prix Galien Canada Research Award. Google it. Big Pharma is anticipating covid19 mutations and will buy them up. $GILD $LLY $PFE $AMGN $REGN $GNUS
  • A
    AIKIDO
    Crazy 25 million shares are short holding the market cap below $6B maybe orchestrated by BP wanting to buy AMRN cheap or Institutions loading at cheap price about to end, the short squeezes will be epic, A monster drug in the making deserve a higher valuations, A $50B to $100B market cap in a few years if GIA same as $AMGN before EPOGEN ,
  • d
    dude
    $EVOK conversation
    Look at $abbv breaking out to the upside and $amgn moving back up. Will bring a lot of small players along too after brutal last few months in biotech pharma. Want to see more M&A also, that’s what we need as tech money shifts to healthcare.
  • A
    AIKIDO
    $VSTM should play catch up to $MRTX KRAS worth $3.8B and $AMGN , a nice partnership is welcome
  • A
    AIKIDO
    AMRN, let’s check the numbers HCW price target is $51 base on 6M target population, now with Reduced it/ CVD the new population target jump to 60M to 70M so , what’s gonna be Analysts price target now? Think BP $PFE $NVS $AMGN $AZN $BIIB $GILD $ABBV should partner or buyout, so many lives will be saved
  • A
    AIKIDO
    AMRN wooow massive shorts burning is near should be closer to $51 target, $GILD $PFE $AMGN $JNJ $LLY partnership or buyout either one will be great
  • B
    Biogemfinder1
    $EXEL conversation
    If $EXEL is looking to diversify & add molecules in the clinic quickly w/ premier bi-specific Ab, then it needs to look into collaboration w/ $XNCR .Their collaboration with Genentech $RHHB Janssen $amgn $NVS
    MDAnderson morphosys $MOR Alexion $alxn Astellas (Japan) validates XNCR's technology. It's at least worth a look and there could be hugely beneficial arrangements for both parties. Xencor has very rich pipeline already and I am sure would be happy to have a partner take over some of these advanced molecules as well as with their excellent and much sought after bi-specific technology and premiere engineering platform, have many in early preclinical development. Doesn't mean EXEL needs to jump in but some due diligence and potential partnership would be time well spent. Bi-specific technology of biologics would nicely complement Exelixis' small molecule and ADC pipeline and collaborations.